Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial
Article first published online: 15 FEB 2006
Copyright © 2006 Wiley-Liss, Inc.
Volume 66, Issue 8, pages 811–821, 1 June 2006
How to Cite
Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linné, C., Richter, K., Löbel, B., Hakenberg, O. W., Hoelig, K., Rieber, E. P. and Wirth, M. P. (2006), Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate, 66: 811–821. doi: 10.1002/pros.20404
- Issue published online: 21 APR 2006
- Article first published online: 15 FEB 2006
- Manuscript Accepted: 1 DEC 2005
- Manuscript Received: 20 SEP 2005
- T-cell response;
- dendritic cells;
- ELISPOT assay;
- hormone-refractory prostate cancer;
Immunotherapies might represent promising alternatives for the treatment of patients with hormone-refractory prostate cancer (HRPC). In a Phase I clinical trial, we evaluated a vaccination with dendritic cells (DCs) loaded with a cocktail consisting of HLA-A*0201-restricted peptides derived from five different prostate cancer-associated antigens [prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), survivin, prostein, transient receptor potential p8 (trp-p8)].
Eight HRPC patients received a total of four vaccinations every other week. Clinical and immunological responses were monitored by the determination of the serum PSA levels and by enzyme linked immunospot (ELISPOT) analyses, respectively.
Apart from local skin reactions no side effects were noted. One patient displayed a partial response (PR; PSA decrease >50%) and three other patients showed stable PSA values or decelerated PSA increases. In ELISPOT analyses, three of four PSA responders also showed antigen-specific CD8+ T-cell activation against prostein, survivin, and PSMA.
The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail-derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa. Prostate © 2006 Wiley-Liss, Inc.